根据名称进行药物检索

Colchicine 与 Nilotinib

Colchicine 与 Nilotinib互相作用以及同时服用的可能性。

检测结果:

Colchicine <> Nilotinib

现实性: 15.10.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

尼可能会增加血液水平的秋水仙素到危险水平，增加的风险严重的副作用，可能会影响你的肌肉细胞，神经系统多器官包括肝脏和肾脏。你可能需要较低剂量的秋水仙素，如果你是当前正在使用尼或有用，它在过去14天。让你的医生知道，如果你遇到腹部疼痛、恶心、呕吐、腹泻、发烧、肌肉疼痛、弱点、疲劳，并且/或者麻木或刺痛你的手和脚，因为这些可能是早期的症状秋水仙素中毒。你不能服用这些药物在一起如果你有肝脏或肾脏疾病。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

调节剂量：共同给予的抑制剂P-糖蛋白(P-gp)可能会显着增加，血清浓度秋水仙素. 该机制涉及增强吸收以及减少排泄秋水仙素由于抑制的P-gp外排转运中的肠肾近端曲小管，以及肝脏。在研究23健康志愿者，管理一个单一的0.6毫克的剂量的秋水仙素组合的一个100毫克的剂量的有效P-gp抑制剂cyclosporine导致大约3.5倍增加在秋水仙素的峰值等离子浓度(C)和系统暴露(AUC)。临床表现形式与相互作用已经包括neuromyopathy,横纹肌瘤,肝和肾毒性的,心脏毒性、骨髓抑制，多器官衰竭和死亡。在回顾性研究的肾移植接受者在一个法国的医院，调查人员报告说，五十病人接受孢菌素结合秋水仙素有经验的肌症状，而没有没有在控制小组，只收到孢菌素. 肌肉组织学，当执行，是一致的，与以前的报告的秋水仙素(即，液泡)肌病。平均持续时间秋水仙素治疗是12.2个月患有肌症状和6.8个月的患者没有肌症状。所有五个患者改善后秋水仙素撤出。没有发现重大差异对于年龄、性别比率、移植的持续时间，血清肌酸酐水平，或累积性类固醇剂量之间的情况下，患者和控制。数据不可用于秋水仙素结合其他P-gp抑制剂。然而，类似的相互作用。

管理：由于风险的威胁生命和致命的毒性，患有肾或肝功能损害不应该给予秋水仙素的组合与P-糖蛋白抑制剂，如环孢霉素、维、胺碘酮、bepridil奎尼丁、奎宁、普罗帕酮，雷诺嗪,螺内,他,醋酸乌利司他和一些酪氨酸酶抑制剂。在患者正常肾和肝功能，剂量的秋水仙素应该减少使用时与P-gp抑制剂或在14天内使用它们。一些当局有指定调整剂量痛风(治疗和预防)以及家庭地中海热病。为治疗严重痛风耀斑，经调整的推荐剂量为0.6毫克的一个剂量。政府不应该重复至少三天。用于治疗的家庭地中海热，最大剂量的秋水仙素是0.6毫克/天(也可以给出为0.3毫克每天两次)使用时存在的一个P-gp抑制剂。患者应该建议联系他们的医生如果他们经历的症状的毒性，例如腹部疼痛、恶心、呕吐、腹泻、疲劳，肌痛乏力、hyporeflexia，感觉异常，麻木。

来源

Kuncl RW, Duncan G, Watson D, et al "Colchicine myopathy and neuropathy." N Engl J Med 316 (1987): 1562-8
Garrouste C, Philipponnet C, Kaysi S, Enache I, Tiple A, Heng AE "Severe colchicine intoxication in a renal transplant recipient on cyclosporine." Transplant Proc 44 (2012): 2851-2
Jonsson J, Gelpi JR, Light JA, Aquino A, Maszaros S "Colchicine-induced myoneuropathy in a renal transplant patient." Transplantation 53 (1992): 1369-71
Volpe DA, Hamed SS, Zhang LK "Use of different parameters and equations for calculation of IC50 values in efflux assays: potential sources of variability in IC 50 determination." AAPS J 16 (2014): 172-80
Mounier G, Guy C, Beyens MN, Ratrema M, Massol A, Ollagnier M "Colchicine-induced pancytopenia during therapeutic dose administratioin. French parmacovigilance database survey and literature review." Drug Saf 29 (2006): 911-1010
FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals: New safety information for Colchicine (marketed as Colcrys). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfess" ([2009 Oct]):
Menta R, Rossi E, Guariglia A, David S, Cambi V "Reversible acute cyclosporin nephrotoxicity induced by colchicine administration." Nephrol Dial Transplant 2 (1987): 380-1
Wilbur K, Makowsky M "Colchicine myotoxicity: case reports and literature review." Pharmacotherapy 24 (2004): 1784-92
Arellano F, Krupp P "Muscular disorders associated with cyclosporin." Lancet 337 (1991): 915
Francis L, Bonilla E, Soforo E, et al. "Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin." Clin Rheumatol 27 (2008): 129-31
Gruberg L, Har-Zahav Y, Agranat O, Freimark D "Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter." Transplant Proc 31 (1999): 2157-8
Rieger EH, Halasz NA, Wahlstrom HE "Colchicine neuromyopathy after renal transplantation." Transplantation 49 (1990): 1196-8
Yussim A, Barnathan N, Lustig S, Shaharabani E, Geier E, Shmuely D, Nakache R, Shapira Z "Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine-colchicine interaction in renal transplantation." Transplant Proc 26 (1994): 2825-6
Nakamura T, Kakumoto M, Yamashita K, et al "Factors influencing the prediction of steady state concentrations of digoxin." Biol Pharm Bull 24 (2001): 403-8
Speeg KV, Maldonado AL, Liaci J, Muirhead D "Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo." J Pharmacol Exp Ther 261 (1992): 50-5
Fujii Y, Arimura Y, Takahashi N, et al. "[A case of Behcet's disease associated with neuromyopathy induced by combination therapy with colchicine and cyclosporin]" Ryumachi 43 (2003): 44-50
FDA. U.S. Food and Drug Administration "Postmarket drug safty information for patients and providers. Drugs. Colchicine (marketed as Colcrys) information. Available from: URL: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm174382.htm." ([2009 Oct]):
Vasudevan AR, Uthamalingam S, Kumar S, Tamarin F, Brensilver JM "Colchicine-induced rhabdomyolysis: the whole is greater than the sum of its parts!" Am J Med 115 (2003): 249
Minetti EE, Minetti L "Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine." J Nephrol 16 (2003): 421-5
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Lee BI, Shin SJ, Yoon SN, Choi YJ, Yang CW, Bang BK "Acute myopathy induced by colchicine in a cyclosporine-treated renal transplant recipient--a case report and review of the literature." J Korean Med Sci 12 (1997): 160-1
Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H "Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring." BMC Med 2 (2004): 8
"Product Information. Colcrys (colchicine)." AR Scientific Inc, Philadelphia, PA.
"Colchicine: serious interactions." Prescrire Int 17 (2008): 151-3
Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R "Colchicine-induced toxicity in a heart transplant patient with chronic renal failure." Clin Toxicol (Phila) 46 (2008): 827-30
Caglar K, Safali M, Yavuz I, Odabasi Z, Yenicesu M, Vural A "Colchicine-induced myopathy with normal creatine phosphokinase level in a renal transplant patient." Nephron 92 (2002): 922-924
Rumpf KW, Henning HV "Is myopathy in renal transplant patients induced by cyclosporin or colchicine?." Lancet 335 (1990): 800-1
Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM "Colchicine myopathy in renal transplant recipients on cyclosporin." Nephrol Dial Transplant 12 (1997): 2389-92